• Media type: E-Article
  • Title: PPAR Activators as Antiinflammatory Mediators in Human T Lymphocytes : Implications for Atherosclerosis and Transplantation-Associated Arteriosclerosis : Implications for Atherosclerosis and Transplantation-Associated Arteriosclerosis
  • Contributor: Marx, Nikolaus; Kehrle, Bettina; Kohlhammer, Klaus; Grüb, Miriam; Koenig, Wolfgang; Hombach, Vinzenz; Libby, Peter; Plutzky, Jorge
  • imprint: Ovid Technologies (Wolters Kluwer Health), 2002
  • Published in: Circulation Research
  • Language: English
  • DOI: 10.1161/01.res.0000014225.20727.8f
  • ISSN: 0009-7330; 1524-4571
  • Origination:
  • Footnote:
  • Description: <jats:p><jats:bold><jats:italic><jats:bold><jats:italic>Abstract—</jats:italic></jats:bold></jats:italic></jats:bold>Activation of T lymphocytes and their ensuing elaboration of proinflammatory cytokines, such as interferon (IFN)-γ, represent a critical step in atherogenesis and arteriosclerosis. IFNγ pathways also appear integral to the development of transplantation-associated arteriosclerosis (Tx-AA), limiting long-term cardiac allograft survival. Although disruption of these IFNγ signaling pathways limits atherosclerosis and Tx-AA in animals, little is known about inhibitory regulation of proinflammatory cytokine production in humans. The present study investigated whether activators of peroxisome proliferator-activated receptor (PPAR)α and PPARγ, with their known antiinflammatory effects, might regulate the expression of proinflammatory cytokines in human CD4-positive T cells. Isolated human CD4-positive T cells express PPARα and PPARγ mRNA and protein. Activation of CD4-positive T cells by anti-CD3 monoclonal antibodies significantly increased IFNγ protein secretion from 0 to 504±168 pg/mL, as determined by ELISA. Pretreatment of cells with well-established PPARα (WY14643 or fenofibrate) or PPARγ (BRL49653/rosiglitazone or pioglitazone) activators reduced anti-CD3-induced IFNγ secretion in a concentration-dependent manner. PPAR activators also inhibited TNFα and interleukin-2 protein expression. In addition, PPAR activators markedly reduced cytokine mRNA expression in these cells. Such antiinflammatory actions were also evident in cell-cell interactions with medium conditioned by PPAR activator-treated T cells attenuating human monocyte CD64 expression and human endothelial cell major histocompatibility complex class II induction. Thus, activation of PPARα and PPARγ in human CD4-positive T cells limits the expression of proinflammatory cytokines, such as IFNγ, yielding potential therapeutic benefits in pathological processes, such as atherosclerosis and Tx-AA.</jats:p>
  • Access State: Open Access